Regimen Reference Order – BRST – trastuzumab Metastatic every 21 days

Planned Course: **Every 21 days until disease progression or unacceptable toxicity**
Indication for Use: **Breast Cancer, Metastatic HER2 positive**

CVAD: At Provider's Discretion

Blood work at provider's discretion: not required to proceed with treatment

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – BRST – trastuzumab (Metastatic) every 21 days

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
Cycle 1		
trastuzumab (brand name specific)	8 mg/kg Loading Dose	IV in normal saline 250 mL over 90 minutes **Alert*: *Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order*
Cycle 2 onwards		
trastuzumab (brand name specific)	6 mg/kg	IV in normal saline 250 mL over 30 minutes **Alert*: *Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order*
All doses will be automatically rounded that fall within the DSG Approved Dose Bands. See BRST DSG – Dose Banding document for more information		

In the event of an infusion-related hypersensitivity reaction, refer to the '**Hypersensitivity Reaction Standing Order'**

REQUIRED MONITORING

Cardiac monitoring

- Left Ventricular Ejection Fraction (LVEF) monitoring recommended:
  - At baseline, and
  - every 4 cycles for the first 2 years, and then
  - every 4 to 8 cycles thereafter

Cycle 1 Only

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) at baseline and as clinically indicated
- Observe patient for 30 minutes after administration of trastuzumab. Full vital signs prior to discharge

Cycles 2 and Onwards

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) at baseline and as clinically indicated
- No observation period required after trastuzumab administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
None required		

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge

ADDITIONAL INFORMATION

- Reassess dose with clinically significant weight changes
- trastuzumab may be used in combination with various chemotherapy regimens
- trastuzumab is available from more than one manufacturer and uses several different brand names. Brand name will be indicated in brackets after trastuzumab. **Ensure prescription label matches the brand name on prescribed order**